Strategic Partnerships OYAGEN holds exclusive rights to RNA and DNA editing technologies from URMC, TJU, and Oregon Health Science Center, presenting a strong opportunity to partner with academic spinouts and research centers for collaborative drug discovery programs and fee-for-service assays.

HIV Focus Upsell With an emphasis on editing enzymes to counteract HIV, there is potential to position OYAGEN as a specialized collaborator for biotech firms seeking novel antiviral platforms, especially around Vif and APOBEC3G targets for enhanced resistance management.

Covid/Therapeutic Expansion Tonix’s exclusive license for TNX-3500 signals a channel for co-development or rights transfer discussions for COVID-19 and related viral therapies, offering cross-sell opportunities to entities pursuing RNA/DNA editing–based antivirals.

Fee-for-Service Engine OYAGEN’s active consulting and high throughput screening services in assay development, biochemistry, structural biology, and virology create a recurring revenue track and a gateway for tiered collaborations with research institutions and biotech startups.

Early-Stage Investment Signals With modest headcount and early-stage funding plus revenue in the low millions, there is an opportunity to engage early-stage biotech investors and strategic buyers seeking innovative editing enzyme platforms as portfolio diversification.